Founded in 2019, Artiva Biotherapeutics is a biotech company based in San Diego. They focus on advancing a pipeline of allogeneic NK cell therapies, including CAR-NK cell therapies, for the treatment of hematologic cancers and solid tumors. Their mission is to deliver safe and effective cell therapies that are readily available to cancer patients. With their unique manufacturing and engineering capabilities, Artiva's platform offers scalability, quality, and cryopreservation to support the development of versatile and accessible product candidates. Their pipeline includes AB-101, an NK-cell therapy used in combination with monoclonal antibodies, as well as CAR-NK programs such as AB-201 for HER2+ solid tumors and AB-202 for B-cell malignancies.